Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer

Inclusion Criteria: 1. Histologically or cytologically confirmed breast cancer that is either metastatic or young breast cancer(≤ 40 years of age). 2. HER2 positive patient who failed HER2 target therapy including trastuzumab with feasible biopsy site. 3. Triple Negative Breast Cancer patient who failed standard therapy with feasible biopsy site. 4. Hormone Receptor positive patient who failed standard therapy with feasible biopsy site. 5. Age ≥ 21 years 6. Written informed consent Exclusion Criteria: 1. No feasible biopsy site 2. No written informed consent